ABHD10

Summary

ABHD10 (abhydrolase domain containing 10, depalmitoylase, HGNC:25656) is a protein-coding gene on chromosome 3q13.2, encoding Palmitoyl-protein thioesterase ABHD10, mitochondrial (Q9NUJ1). Acts as an acyl-protein thioesterase that hydrolyzes fatty acids from acylated residues in proteins.

This gene encodes a mitochondrially-localized enzyme that acts in liver cells as a hydrolase. The encoded protein removes glucuronide from mycophenolic acid acyl-glucuronide. There is a pseudogene for this gene on chromosome 6. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 55347 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 78 total — 8 pathogenic
• Druggable target: yes
• MANE Select transcript: NM_018394

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25656
Approved symbol	ABHD10
Name	abhydrolase domain containing 10, depalmitoylase
Location	3q13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ11342
Ensembl gene	ENSG00000144827
Ensembl biotype	protein_coding
OMIM	618756
Entrez	55347

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 6 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000273359, ENST00000491580, ENST00000493784, ENST00000494817, ENST00000497293, ENST00000884616, ENST00000916260, ENST00000916261, ENST00000916262

RefSeq mRNA: 2 — MANE Select: NM_018394 NM_001272069, NM_018394

CCDS: CCDS2963, CCDS63718

Canonical transcript exons

ENST00000273359 — 5 exons

Exon	Start	End
ENSE00000967357	111981784	111981967
ENSE00001200297	111991377	111993368
ENSE00001825875	111979026	111979203
ENSE00003463040	111986264	111986375
ENSE00003572494	111986914	111987051

Expression profiles

Bgee: expression breadth ubiquitous, 289 present calls, max score 95.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 20.3323 / max 258.3651, expressed in 1799 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
37903	19.0331	1793
37902	1.2992	904

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
nephron tubule	UBERON:0001231	95.32	gold quality
corpus epididymis	UBERON:0004359	94.95	gold quality
middle temporal gyrus	UBERON:0002771	94.20	gold quality
adrenal tissue	UBERON:0018303	93.43	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.29	gold quality
kidney epithelium	UBERON:0004819	93.26	gold quality
renal glomerulus	UBERON:0000074	92.98	gold quality
calcaneal tendon	UBERON:0003701	92.83	gold quality
metanephric glomerulus	UBERON:0004736	92.82	gold quality
islet of Langerhans	UBERON:0000006	92.77	gold quality
cerebellar vermis	UBERON:0004720	92.05	gold quality
adenohypophysis	UBERON:0002196	91.74	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.60	gold quality
periodontal ligament	UBERON:0008266	91.52	gold quality
renal medulla	UBERON:0000362	91.51	gold quality
parotid gland	UBERON:0001831	91.48	gold quality
cortex of kidney	UBERON:0001225	91.40	gold quality
cortical plate	UBERON:0005343	91.39	gold quality
pituitary gland	UBERON:0000007	91.27	gold quality
Brodmann (1909) area 23	UBERON:0013554	91.23	gold quality
left ventricle myocardium	UBERON:0006566	91.21	gold quality
kidney	UBERON:0002113	91.14	gold quality
ventricular zone	UBERON:0003053	91.11	gold quality
adult mammalian kidney	UBERON:0000082	91.08	gold quality
nucleus accumbens	UBERON:0001882	90.74	gold quality
caput epididymis	UBERON:0004358	90.66	gold quality
corpus callosum	UBERON:0002336	90.61	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.53	gold quality
cranial nerve II	UBERON:0000941	90.44	gold quality
right adrenal gland cortex	UBERON:0035827	90.34	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.83

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting ABHD10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-2681-5P	99.75	67.64	1655
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-4743-3P	99.62	68.12	2095

Literature-anchored findings (GeneRIF, showing 3)

• mitochondrial localization of rat Abhd10 (PMID:21078990)
• ABHD10 is responsible for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. (PMID:22294686)
• Which potently inhibited ABHD10 activity. (PMID:25217485)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tagln3b	ENSDARG00000058394
danio_rerio	abhd10a	ENSDARG00000076435
mus_musculus	Abhd10	ENSMUSG00000033157
rattus_norvegicus	Abhd10	ENSRNOG00000054334

Protein

Protein identifiers

Palmitoyl-protein thioesterase ABHD10, mitochondrial — Q9NUJ1 (reviewed: Q9NUJ1)

Alternative names: Acyl-protein thioesterase ABHD10, Alpha/beta hydrolase domain-containing protein 10, Mycophenolic acid acyl-glucuronide esterase, mitochondrial

All UniProt accessions (3): Q9NUJ1, F8WBJ5, F8WBQ6

UniProt curated annotations — full annotation on UniProt →

Function. Acts as an acyl-protein thioesterase that hydrolyzes fatty acids from acylated residues in proteins. Regulates the mitochondrial S-depalmitoylation of the nucleophilic active site residue of peroxiredoxin-5/PRDX5, a key antioxidant protein, therefore modulating mitochondrial antioxidant ability. Also catalyzes the deglucuronidation of mycophenolic acid acyl-glucuronide, an active metabolite of the immunosuppressant drug mycophenolate.

Subcellular location. Mitochondrion.

Activity regulation. Inhibited by palmostatin-B.

Similarity. Belongs to the AB hydrolase superfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NUJ1-1	1	yes
Q9NUJ1-2	2
Q9NUJ1-3	3

RefSeq proteins (2): NP_001258998, NP_060864* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000073	AB_hydrolase_1	Domain
IPR029058	AB_hydrolase_fold	Homologous_superfamily
IPR052382	ABHD10_acyl-thioesterase	Family

Pfam: PF00561

Enzyme classification (BRENDA):

• EC 3.1.1.93 — mycophenolic acid acyl-glucuronide esterase (BRENDA: 1 organisms, 1 substrates, 15 inhibitors, 1 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
MYCOPHENOLIC ACID O-ACYL-GLUCURONIDE	0.1007	1

Catalyzed reactions (Rhea), 2 shown:

• S-hexadecanoyl-L-cysteinyl-[protein] + H2O = L-cysteinyl-[protein] + hexadecanoate + H(+) (RHEA:19233)
• mycophenolic acid O-acyl-beta-D-glucuronide + H2O = mycophenolate + D-glucuronate + H(+) (RHEA:34179)

UniProt features (11 total): active site 3, splice variant 3, transit peptide 1, chain 1, mutagenesis site 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NUJ1-F1	86.70	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 152 (charge relay system); 249 (charge relay system); 279 (charge relay system)

Mutagenesis-validated functional residues (1):

Position	Phenotype
152	loss of palmitoyl-(protein) hydrolase activity.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-156588	Glucuronidation
R-HSA-1430728	Metabolism
R-HSA-156580	Phase II - Conjugation of compounds
R-HSA-211859	Biological oxidations

MSigDB gene sets: 163 (showing top): REACTOME_BIOLOGICAL_OXIDATIONS, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, FISCHER_G1_S_CELL_CYCLE, GOBP_MACROMOLECULE_DEACYLATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, ZHOU_INFLAMMATORY_RESPONSE_LIVE_DN, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, FISCHER_DREAM_TARGETS, GOBP_PROTEIN_CATABOLIC_PROCESS, MULLIGHAN_MLL_SIGNATURE_2_DN, GOCC_MITOCHONDRIAL_MATRIX, MARSON_BOUND_BY_E2F4_UNSTIMULATED, REACTOME_GLUCURONIDATION

GO Biological Process (3): protein depalmitoylation (GO:0002084), xenobiotic metabolic process (GO:0006805), glucuronate metabolic process (GO:0019585)

GO Molecular Function (5): hydrolase activity, hydrolyzing O-glycosyl compounds (GO:0004553), palmitoyl-(protein) hydrolase activity (GO:0008474), mycophenolic acid acyl-glucuronide esterase activity (GO:0102390), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Phase II - Conjugation of compounds	1
Biological oxidations	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
protein deacylation	1
lipoprotein catabolic process	1
macromolecule depalmitoylation	1
metabolic process	1
cellular response to xenobiotic stimulus	1
monocarboxylic acid metabolic process	1
hydrolase activity, acting on glycosyl bonds	1
thiolester hydrolase activity	1
palmitoyl hydrolase activity	1
catalytic activity, acting on a protein	1
carboxylic ester hydrolase activity	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
mitochondrion	1
intracellular organelle lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1610 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ABHD10	ABHD17A	Q96GS6	682
ABHD10	ABHD11	Q8NFV4	605
ABHD10	ABHD13	Q7L211	601
ABHD10	ABHD17B	Q5VST6	589
ABHD10	ABHD3	Q8WU67	556
ABHD10	ABHD6	Q9BV23	553
ABHD10	ABHD16B	Q9H3Z7	553
ABHD10	ABHD12B	Q7Z5M8	548
ABHD10	ABHD16A	O95870	541
ABHD10	ABHD1	Q96SE0	530
ABHD10	ABHD14B	Q96IU4	527
ABHD10	LYPLA1	O75608	519
ABHD10	ABHD4	Q8TB40	518
ABHD10	ABHD2	P08910	500
ABHD10	ABHD14A	Q9BUJ0	500

IntAct

59 interactions, top by confidence:

A	B	Type	Score
ASH2L	KMT2D	psi-mi:“MI:0914”(association)	0.890
ARL3	UNC119B	psi-mi:“MI:0914”(association)	0.730
FOXK2	DVL2	psi-mi:“MI:0914”(association)	0.640
INPP5K	GART	psi-mi:“MI:0914”(association)	0.640
KCMF1	IDH2	psi-mi:“MI:0914”(association)	0.530
ABHD10	UBR5	psi-mi:“MI:0914”(association)	0.530
IMPDH1	BCAT2	psi-mi:“MI:0914”(association)	0.530
PIGT	ZNF609	psi-mi:“MI:0914”(association)	0.530
HSPBAP1	ABHD10	psi-mi:“MI:0915”(physical association)	0.500
ACSF3	ABHD10	psi-mi:“MI:0915”(physical association)	0.400
	TK2	psi-mi:“MI:0915”(physical association)	0.400
Ubr5	SFI1	psi-mi:“MI:0914”(association)	0.350
FOXK1	PHKG2	psi-mi:“MI:0914”(association)	0.350
E7	COPE	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
ARL3		psi-mi:“MI:0914”(association)	0.350
IFIH1	DDHD2	psi-mi:“MI:0914”(association)	0.350
IFIH1	FAM168B	psi-mi:“MI:0914”(association)	0.350
DLD	NFKBIE	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
INPP5K	PES1	psi-mi:“MI:0914”(association)	0.350
FMC1	NDUFAB1	psi-mi:“MI:0914”(association)	0.350
FMC1	DNM1L	psi-mi:“MI:0914”(association)	0.350
OPA3	NDUFS8	psi-mi:“MI:0914”(association)	0.350
COQ7	ALDH1L1	psi-mi:“MI:0914”(association)	0.350
FAM136A	ALDH1L1	psi-mi:“MI:0914”(association)	0.350
LACTB	ALDH1L1	psi-mi:“MI:0914”(association)	0.350
OPA3	CS	psi-mi:“MI:0914”(association)	0.350
PRKCI	POLRMT	psi-mi:“MI:0914”(association)	0.350

BioGRID (121): ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Affinity Capture-MS), ABHD10 (Proximity Label-MS), ABHD10 (Proximity Label-MS)

ESM2 similar proteins: A0JPF9, A2AV36, A2VD33, A3KP77, A4IGH2, A4IHY0, A6QQV6, A8E7D2, B0S8I0, E1BCH6, E1BVR9, E9PYK3, P0C5J1, P57075, P83006, Q28CZ7, Q32PY6, Q3U3W5, Q3UZW7, Q3V3E1, Q4V7D6, Q502I6, Q58DM7, Q5E9H9, Q5I0K5, Q5M7E3, Q5R4D2, Q5REX5, Q5RG49, Q5RJG7, Q5S6T3, Q5U4E8, Q5ZIB9, Q66KI9, Q6PCI6, Q6PE15, Q7T0X7, Q8BGG7, Q8BTK5, Q8L5Z4

Diamond homologs: Q5E9H9, Q5I0K5, Q5REX5, Q6PE15, Q99390, Q9NUJ1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

78 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	8
Likely pathogenic	0
Uncertain significance	52
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (8)

Variant ID	HGVS	Classification
1703653	GRCh37/hg19 3q13.12-13.31(chr3:106598767-115704696)	Pathogenic
1807773	GRCh37/hg19 3q13.12-13.31(chr3:107059705-115005256)x1	Pathogenic
2498335	GRCh37/hg19 3q13.13-13.31(chr3:110966195-115843176)x1	Pathogenic
393800	GRCh37/hg19 3q13.11-13.32(chr3:105094834-117441953)x1	Pathogenic
562805	GRCh37/hg19 3q13.13-13.31(chr3:110645295-115103586)x1	Pathogenic
57804	GRCh38/hg38 3q13.13-13.31(chr3:108242572-116169331)x1	Pathogenic
57980	GRCh38/hg38 3q13.11-13.31(chr3:104621220-116093884)x3	Pathogenic
814468	GRCh37/hg19 3q12.3-13.2(chr3:101812245-112174485)x1	Pathogenic

SpliceAI

757 predictions. Top by Δscore:

Variant	Effect	Δscore
3:111986388:T:G	donor_gain	1.0000
3:111986388:T:TG	donor_gain	1.0000
3:111986906:A:AG	acceptor_gain	1.0000
3:111986907:T:G	acceptor_gain	1.0000
3:111986909:TTTA:T	acceptor_loss	1.0000
3:111986912:A:AG	acceptor_gain	1.0000
3:111986913:G:GG	acceptor_gain	1.0000
3:111986913:GA:G	acceptor_gain	1.0000
3:111986913:GAT:G	acceptor_gain	1.0000
3:111986913:GATT:G	acceptor_gain	1.0000
3:111986913:GATTC:G	acceptor_gain	1.0000
3:111987047:TTGAG:T	donor_gain	1.0000
3:111987048:TGAG:T	donor_gain	1.0000
3:111987049:GAG:G	donor_gain	1.0000
3:111987049:GAGG:G	donor_gain	1.0000
3:111987049:GAGGT:G	donor_loss	1.0000
3:111987050:AG:A	donor_gain	1.0000
3:111987051:GG:G	donor_gain	1.0000
3:111987051:GGTA:G	donor_loss	1.0000
3:111987052:G:GG	donor_gain	1.0000
3:111987052:GTAA:G	donor_loss	1.0000
3:111990752:G:GG	donor_gain	1.0000
3:111991372:A:AG	acceptor_gain	1.0000
3:111991373:A:G	acceptor_gain	1.0000
3:111991375:A:AG	acceptor_gain	1.0000
3:111991375:AGC:A	acceptor_loss	1.0000
3:111991376:G:GA	acceptor_gain	1.0000
3:111991376:GC:G	acceptor_gain	1.0000
3:111991376:GCT:G	acceptor_gain	1.0000
3:111991376:GCTA:G	acceptor_gain	1.0000

AlphaMissense

1989 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:111986941:T:A	W156R	0.988
3:111986941:T:C	W156R	0.988
3:111986969:G:C	R165P	0.988
3:111986921:T:A	V149D	0.987
3:111986959:G:C	A162P	0.987
3:111991545:G:C	D249H	0.986
3:111986936:G:A	G154E	0.985
3:111991528:T:C	L243S	0.985
3:111986956:G:C	A161P	0.984
3:111986986:G:C	A171P	0.984
3:111986924:G:A	G150E	0.983
3:111986936:G:T	G154V	0.983
3:111986957:C:A	A161D	0.983
3:111986990:T:C	L172P	0.983
3:111991473:G:C	A225P	0.983
3:111986915:T:C	I147T	0.982
3:111986915:T:G	I147S	0.982
3:111986929:A:C	S152R	0.982
3:111986931:C:A	S152R	0.982
3:111986931:C:G	S152R	0.982
3:111986960:C:A	A162E	0.982
3:111986996:G:A	G174D	0.981
3:111986935:G:A	G154R	0.980
3:111986935:G:C	G154R	0.980
3:111986987:C:A	A171D	0.980
3:111986995:G:C	G174R	0.980
3:111981941:C:G	C100W	0.978
3:111986915:T:A	I147N	0.977
3:111991537:G:A	G246D	0.975
3:111981936:T:C	F99L	0.974

dbSNP variants (sampled 300 via entrez): RS1000133176 (3:111977775 A>T), RS1000244554 (3:111978749 T>C), RS1000430212 (3:111989770 A>G,T), RS1000515210 (3:111988786 C>T), RS1000761831 (3:111988319 T>TA), RS1000899348 (3:111989053 C>T), RS1000953972 (3:111982560 C>A,G), RS1001067004 (3:111983019 A>G), RS1001645478 (3:111977590 C>T), RS1001873408 (3:111980772 A>G), RS1002414661 (3:111987594 C>T), RS1002416345 (3:111982194 A>C), RS1002535308 (3:111991963 T>A), RS1002695164 (3:111988425 G>T), RS1002734576 (3:111987350 T>G)

Disease associations

OMIM: gene MIM:618756 | disease phenotypes: MIM:615433

GenCC curated gene-disease

Mondo (1): chromosome 3q13.31 deletion syndrome (MONDO:0014185)

Orphanet (1): 3q13 microdeletion syndrome (Orphanet:1621)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009391_643	Metabolite levels	6.000000e-06
GCST011773_26	Type 1 diabetes (age at diagnosis)	5.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010504	inositol measurement
EFO:0004918	age at diagnosis

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C536808	Chromosome 3, monosomy 3q13 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066317 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.52	IC50	30	nM	CHEMBL2136724
7.00	IC50	100	nM	CHEMBL5562401
6.68	IC50	210	nM	CHEMBL1316155

PubChem BioAssay actives

3 with measured affinity, of 3 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
dipropan-2-yl (3R)-3-ethyl-3-(4-methylphenyl)-4-oxodiazetidine-1,2-dicarboxylate	2084141: Inhibition of ABHD10 (unknown origin)	ic50	0.0300	uM
(1S,9R,10S,11R,14R)-1-hydroxy-3,5-dimethoxy-9-(4-methoxyphenyl)-10-phenyl-8,13-dioxatetracyclo[7.5.0.02,7.011,14]tetradeca-2(7),3,5-trien-12-one	2084141: Inhibition of ABHD10 (unknown origin)	ic50	0.1000	uM
dimethyl (3R)-3-ethyl-3-(3-methylphenyl)-4-oxodiazetidine-1,2-dicarboxylate	2084141: Inhibition of ABHD10 (unknown origin)	ic50	0.2100	uM

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression	2
Cyclosporine	increases expression	2
Cadmium Chloride	increases expression, increases abundance	2
aristolochic acid I	increases expression	1
bisphenol F	increases expression	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
perfluorooctanoic acid	increases expression	1
ochratoxin A	affects cotreatment, decreases expression	1
bleomycetin	decreases expression	1
nickel sulfate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
di-n-butylphosphoric acid	affects expression	1
K 7174	decreases expression	1
bisphenol B	increases expression	1
abrine	decreases expression	1
(4-amino-1,4-dihydro-3-(2-pyridyl)-5-thioxo-1,2,4-triazole)copper(II)	decreases expression	1
bisphenol S	increases expression	1
bisphenol AF	increases expression	1
Sunitinib	increases expression	1
Cadmium	increases abundance, increases expression	1
Citrinin	affects cotreatment, decreases expression	1
Dinitrochlorobenzene	decreases expression	1
Estradiol	increases expression	1
Ivermectin	decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5524614	Binding	Inhibition of ABHD10 (unknown origin)	Modulators for palmitoylation of proteins and small molecules. — Eur J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.